메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Significant Improvement in Quality of Life Reported in Updated…

HONG KONG, Dec. 9, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by Professor Shun Lu from Shanghai Chest Hospital. The study evaluates ivonescimab (a first-in-class PD-1/VEGF bispecific antibody) combined with chemotherapy versus tislelizumab combined with chemotherapy in first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). Beyond the previously reported efficacy data presen
- 김갑성 기자
- 2025-12-09 10:02
Therme Group acquires full Thermengruppe Josef Wund po…

MUNICH, Dec. 9, 2025 -- Therme Group, a leading developer, owner and operator shaping the future of wellbeing infrastructure, today announced the acquisition of three thermal wellbeing destinations — Euskirchen, Sinsheim, and Titisee-Neustadt — from the Josef Wund Foundation. The transaction is subject to approval by the German Federal Cartel Office. Completed through Therme Horizon, Therme Group's joint venture with CVC Capital Partners, the acquisition brings three additional world-class destinations into the Therme ecosystem. Together with the 2024 acquisition of Therme Erdi
- 김갑성 기자
- 2025-12-09 09:00
CGTN: In the wake of tragedy, Hong Kong comes together to…

BEIJING, Dec. 9, 2025 -- CGTN published an article on the post-disaster rescue and reconstruction efforts following a devastating fire in Tai Po in the Hong Kong Special Administrative Region (HKSAR), highlighting the collective efforts by the central government and the HKSAR government, Hong Kong residents, volunteers from the mainland, and different sectors of society. At Wang Fuk Court in Tai Po, residents have quietly returned to homes they'll never be able to live in again – some for the first time since the devastating fire on November 26. Many came only to retrieve what little t
- 김갑성 기자
- 2025-12-09 08:54
Inheritance + Innovation + Development: The "Co-developm…

HONG KONG, Dec. 9, 2025 -- From November 23 to 25, the Seventh World Hakka Entrepreneurs Convention was held in Meizhou, Guangdong. The conference, with the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development," upheld the principles of "openness, innovation, cooperation, and mutual benefit," and explored new opportunities for the development of Hakka culture and industrial development. At this grand, globally watched event, Guangdong Jiaying Pharmaceutical Co., Ltd. showcased its star products, including "Shuangliao Houfeng San" (Dou
- 김갑성 기자
- 2025-12-09 08:00
Innovent Announces PECONDLE® (Picankibart Injection) Phas…

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that that PECONDLE® (picankibart injection, R&D code: IBI112), its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, achieved both primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study – a random
- 김갑성 기자
- 2025-12-09 08:00
With Child Deaths Projected to Rise for the First Time in a Centu…

[ 메디채널 김갑성 기자 ] At Goalkeepers Abu Dhabi, global leaders outline a path to improve and save the lives of millions of children through lifesaving innovation and renewed investment Partners announce $1.9 billion to advance polio eradication Event held in partnership with the Mohamed bin Zayed Foundation for Humanity highlights urgency, honors leadership, and showcases champions advancing progress despite historic global funding cuts ABU DHABI, UAE, Dec. 9, 2025 -- At Goalkeepers Abu Dhabi, leaders from government, philanthropy, business, and civil society issued a unified
- 김갑성 기자
- 2025-12-09 03:14
EpiVax and FDA Scientists Publish New Insights on Immunoge…

PROVIDENCE, R.I., Dec. 9, 2025 -- EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publication of a study titled "Immunogenicity Risk Assessment of Peptide-Related Impurities Identified in Generic Teriparatide Products." The study uses a series of different tools to evaluate whether peptide-related impurities may influence unwanted immune responses in generic teriparatide (TPT)—an important consideration for ensuring the safety and comparability of generic peptide drugs. Teriparatide, a rec
- 김갑성 기자
- 2025-12-09 03:11
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Com…

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated mean
- 김갑성 기자
- 2025-12-09 03:05
Convergen Secures $10 Million Seed Funding to Advance Tr…

SUZHOU, China, Dec. 8, 2025 -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $10 million Seed financing round. The round was invested by Qiming Venture Partners, a leading global venture capital firm focused on life sciences and healthcare innovation. Funds from the financing will accelerate the development of Convergen's proprietary TrimTAC platform—next-generation bifunctional degraders leveraging the E3 ubiquitin ligase TRIM21—and advance its early
- 김갑성 기자
- 2025-12-08 23:00
Halia Therapeutics Announces Positive Phase 2a Data for O…

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes –– Favorable safety profile with no treatment-related serious adverse events – LEHI, Utah, Dec. 8, 2025 -- Halia Therapeutics, a clinical-stage biopharmaceutical company, today presented new clinical data from its Phase 2a study of ofirnoflast (HT-6184) at the 67th American Society of Hematology (ASH) Annual Meeting. The data show that ofirnoflast, a first-
- 김갑성 기자
- 2025-12-08 22:22

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분